Status:
COMPLETED
A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Non-Squamous Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will evaluate the efficacy and safety of metronidazole actavis 1 percent (%) topical cream in the prevention and treatment of rash associated with Tarceva treatment, in participants with no...
Eligibility Criteria
Inclusion
- non-small cell lung cancer
- eligible to start treatment with erlotinib
Exclusion
- hypersensitivity to metronidazole
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00642473
Start Date
February 1 2008
End Date
March 1 2009
Last Update
May 23 2016
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Gothenburg, Sweden, 41345
2
Lund, Sweden, 22185
3
Malmo, Sweden, 20502
4
Stockholm, Sweden, S-14186